SCHEMBL25199667

SCHEMBL25199667

Cc1ccc(C(=O)/C=C\c2cccc(O)c2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 2/20 0.69
MAPT P10636 5/20 0.67
MAOB P27338 4/20 0.67
MAOA P21397 3/20 0.67
RAB9A P51151 3/20 0.67
POLB P06746 1/20 0.67
MMP1 P03956 1/20 0.63
MMP2 P08253 1/20 0.63
MMP9 P14780 1/20 0.63
P4HB P07237 4/20 0.62
CXCL12 P48061 1/20 0.62
NPC1 O15118 1/20 0.60
ALDH1A1 P00352 2/20 0.59
CYP1A1 P04798 1/20 0.59
CYP1A2 P05177 1/20 0.59
MEN1 O00255 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
KMT2A Q03164 1/20 0.59
RELA Q04206 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30384568 1.00 CYP1B1 (0.69) CYP1B1MAPTMAOBMAOARAB9A
SCHEMBL31233274 1.00 CYP1B1 (0.69) CYP1B1MAPTMAOBMAOARAB9A
SCHEMBL8829842 1.00 CYP1B1 (0.69) CYP1B1MAPTMAOBMAOARAB9A
SCHEMBL8829843 1.00 CYP1B1 (0.69) CYP1B1MAPTMAOBMAOARAB9A
SCHEMBL31233167 0.89 F3 (0.72) CYP1B1MAPTMAOBMAOARAB9A
SCHEMBL2999489 0.89 F3 (0.72) CYP1B1MAPTMAOBMAOARAB9A
SCHEMBL2999487 0.89 F3 (0.72) CYP1B1MAPTMAOBMAOARAB9A
SCHEMBL2388292 0.86 P4HB (0.68) CYP1B1MAOBMAOAMMP1MMP2
SCHEMBL2388296 0.86 P4HB (0.68) CYP1B1MAOBMAOAMMP1MMP2
3-Hydroxy Chalcone SCHEMBL1524799 0.85 P4HB (0.74) CYP1B1MAPTMAOBMAOARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B CYP1B1 230/4885MAPT 3297/4885MAOB 1004/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 CYP1B1 1027/4885MAPT 3512/4885MAOB 2435/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 CYP1B1 1027/4885MAPT 3512/4885MAOB 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.